No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMED240517C95000
- 0.45
- 0.000.00%
15min DelayTrading May 8 13:00 ET
0.00High0.00Low
0.00Open0.45Pre Close0 Volume0 Open Interest95.00Strike Price0.00Turnover231.16%IV-1.36%PremiumMay 17, 2024Expiry Date1.77Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.3759Delta0.2175Gamma215.04Leverage Ratio-14.5326Theta0.0000Rho80.83Eff Leverage0.0029Vega
Intraday
- 5D
- 1D
No Data
News
Express News | Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
Amedisys Inc Releases First-Quarter Supplemental Slides
Express News | Amedisys Inc Q1 Shr View $1.02 -- Lseg Ibes Data
Comments
$Amedisys(AMED.US$ divergency with good fundamental Also gap so it looks good and risk to rewards is acceptable
1
$Inhibikase Therapeutics(IKT.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech(PMCB.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech(PMCB.US$
2
Read more
Kofi : Do u see it going above 100 ?